Toronto, Ontario – April 19, 2013 -- Theralase Technologies Inc.
(TSX-V: TLT) announced today that its innovative Photo Dynamic Compound (PDC) technology
has been accepted for presentation at two major international scientific
conferences. Acceptance at these conferences validates the significance of the technology
and its efficacy in the destruction of cancer cells in research performed by
Theralase's internationally acclaimed scientists.
The efficacy of the anti-cancer Photo Dynamic Compound technology will
be presented at LASER World of Photonics conference in Munich, Germany on May
15, 2013.
The effective destruction of bacteria using Theralase’s light activated
Photo Dynamic Compound technology will be presented at
Photonics North conference in Ottawa, Canada on June 3, 2013.
In further developments, Theralase’s Chief Scientific Officer, Dr.
Arkady Mandel has been elected to the Editorial Board of Photonics & Lasers
in Medicine (PLM) journal and chosen as issue editor of PLM for the Low Level
Laser Therapy (LLLT) issue. PLM is an internationally peer-reviewed journal,
which publishes clinical and scientific studies concerned with the clinical and
scientific application of lasers and biophotonics in medicine for diagnostic
and therapeutic purposes. PLM recently featured the clinical success of Theralase’s
pivotal randomized placebo controlled clinical trial entitled, “Laser Therapy
Applications for Osteoarthritis and Chronic Joint Pain.”
Roger Dumoulin-White, President and CEO of Theralase said, "I am
pleased that Theralase’s scientific and clinical research has been recognized
and acclaimed by two of the finest international scientific conferences and has
been published in a peer reviewed medical journal. Theralase is committed to
the early commercialization of its patented light activated Photo Dynamic
Compounds in the areas of anti-cancer and anti-bacterial applications to generate
substantial revenue increases for the Company. To accelerate this process, we
are actively looking to collaborate with strategic partners to further develop
our
technologies and increase shareholder value. Theralase’s strong PDC pipeline has
scientifically proven that our PDC technology is capable of consistently
producing cell kill levels of 100%, even at very low concentrations, across a
wide range of cancers and bacteria. In fact, our PDCs have been proven to be significantly
more effective in destroying cancer cells and bacteria than currently FDA
approved Photo Dynamic Compounds.”
About
Theralase Technologies Inc.:
Theralase Technologies Inc., founded in 1995, designs, develops,
manufactures and markets patented, superpulsed laser technology utilized in
biostimulation and biodestruction applications. Theralase technology is safe
and effective in treating pain, inflammation and for tissue regeneration of
neural muscular skeletal conditions and wound healing. Theralase is currently
developing patented Photo Dynamic Compounds (PDCs) that are able to target and
destroy cancers, bacteria and viruses when light activated by Theralase’s proprietary
laser technology.
For further information please
visit www.theralase.com , regulatory
filings may be viewed by visiting www.sedar.com.
This press release contains forward-looking statements, which reflect
the Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation to
update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchanges) accepts
responsibility for the adequacy or accuracy of this release.
For More Information
Roger Dumoulin-White
President & CEO
416-699-LASE (5273) ext. 225
rwhite@theralase.com
Kristina Hachey
Chief Financial Officer
416-699-LASE (5273) ext. 224
khachey@theralase.com
Arkady Mandel
Chief Scientific Officer
416-699-LASE (5273) ext. 260
amandel@theralase.com
Greg Bewsh
Director of Investor Relations
416-699-LASE (5273) ext. 258
gbewsh@theralase.com
No comments:
Post a Comment